Welcome to our dedicated page for Globus Med SEC filings (Ticker: GMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Globus Medical, Inc. (NYSE: GMED) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a publicly traded musculoskeletal medical device manufacturer, Globus Medical files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe its operations, risk factors, financial performance, and material events.
Recent Form 8-K filings from Globus Medical have reported preliminary and final net sales and operating results for specific quarters and fiscal years, leadership transitions at the President, Chief Executive Officer, and Chief Financial Officer roles, and other significant corporate developments. These filings often reference earnings press releases furnished as exhibits, which include details on worldwide net sales, U.S. and international performance, non-GAAP financial measures, and guidance for future periods.
Through its filings, Globus Medical also explains its use of non-GAAP metrics such as non-GAAP adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross profit, free cash flow, constant currency net sales growth, and base business sales excluding contributions from recent acquisitions like Nevro Corp. and its subsidiaries. The company describes how these measures adjust for items such as litigation provisions, amortization of intangibles, merger and acquisition-related costs, restructuring-related costs, certain foreign currency impacts, bargain purchase gains, and specific tax effects.
On this page, Stock Titan pairs Globus Medical’s raw SEC documents with AI-powered summaries that highlight the key points of lengthy filings. Users can quickly see what changed in a new 10-K or 10-Q, how management characterizes performance in 8-K earnings releases, and where non-GAAP adjustments have a material impact. The platform also surfaces real-time updates from EDGAR, helping investors follow new filings as they are posted and review the company’s regulatory history in one place.
Globus Medical executive Kelly Huller, EVP, General Counsel and Corporate Secretary, reported an option exercise and share sale. On February 12, 2026, she exercised stock options for 10,000 Class A shares at
The same day, she sold 10,000 Class A shares at
An insider of GMED has filed a Form 144 notice to sell 10,000 shares of common stock through Raymond James & Associates on the NYSE. The shares have an aggregate market value of about $876,000 based on the figures disclosed.
The securities were acquired on 02/12/2026 via a cashless option exercise from the issuer, with the same date listed as the payment date. Over the prior three months, the same seller, Kelly Huller, sold 7,500 common shares for gross proceeds of about $674,620.
Globus Medical director Leslie V. Norwalk received a grant of 15,000 stock options for Class A common stock. The options carry an exercise price of $94.15 per share and were granted as a derivative equity award.
According to the filing, these options were granted on January 21, 2026, will vest on January 1, 2027, and expire on January 21, 2036. After this grant, Norwalk beneficially owns 15,000 derivative securities directly, reflecting a standard director compensation award rather than an open-market transaction.
Globus Medical Inc. reported a new stock option grant to its President and CEO, Keith W. Pfeil. On January 21, 2026, Pfeil received stock options giving him the right to buy 100,000 shares of Class A common stock at an exercise price of
The award vests over four years, with one-quarter of the options vesting on January 1, 2027 and the remaining options vesting in equal monthly installments (1/48 of the total) each month thereafter. All 100,000 options are reported as held directly by Pfeil following this grant.
Globus Medical Senior Vice President and CFO Kyle Kline received a grant of 30,000 stock options to buy Class A common stock at an exercise price of $94.15 per share. The options were granted on January 21, 2026 and were reported as directly owned by Kline. They vest over a four-year period, with one-quarter vesting on January 1, 2027 and the remaining three-quarters vesting in equal monthly installments of 1/48 of the grant each month thereafter, ending on the stated expiration date of January 21, 2036.
Globus Medical Inc. reported that Executive Chairman and director Paul David C, who is also a 10% owner, received a grant of stock options. On January 21, 2026, he was awarded 100,000 stock options to buy Class A common stock at an exercise price of
The options vest over four years, with one quarter vesting on
Globus Medical Inc. director Douglas Robert Andrew received a new stock option grant. On January 21, 2026, he was awarded options to buy 15,000 shares of Class A common stock at an exercise price of $94.15 per share. The filing shows these options were granted for no cash payment at grant.
According to the disclosure, the options will vest on January 1, 2027, meaning they become exercisable on that date, and they expire on January 21, 2036 if not exercised. Following this grant, he beneficially owns 15,000 derivative securities directly in the form of these options.
Globus Medical director Dan Lemaitre received a new stock option grant. On January 21, 2026, he was awarded options to buy 15,000 shares of Class A common stock at an exercise price of
Globus Medical director Ann D. Rhoads received a new stock option award. On January 21, 2026, she was granted options to purchase 15,000 shares of Globus Medical Class A common stock at an exercise price of $94.15 per share. The options were granted at a price of $0 for the derivative itself and are held directly. They will vest on January 1, 2027 and are scheduled to expire on January 21, 2036, giving her a long-term incentive tied to the company’s share performance.
Globus Medical Inc. director James R. Tobin received a grant of stock options on January 21, 2026. The award covers 15,000 stock options to buy Class A common stock at an exercise price of $94.15 per share, with no purchase price for receiving the options themselves.
According to the filing, these options will vest on January 1, 2027 and expire on January 21, 2036 if not exercised earlier. After this grant, Tobin holds 15,000 derivative securities directly, all from this option award. This represents routine equity-based compensation that aligns the director’s interests with the company’s long-term share performance.